CN115666644A - 长效兽用抗il31抗体 - Google Patents

长效兽用抗il31抗体 Download PDF

Info

Publication number
CN115666644A
CN115666644A CN202180036332.3A CN202180036332A CN115666644A CN 115666644 A CN115666644 A CN 115666644A CN 202180036332 A CN202180036332 A CN 202180036332A CN 115666644 A CN115666644 A CN 115666644A
Authority
CN
China
Prior art keywords
antibody
seq
ser
leu
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180036332.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·李
L·阮
Q·楚
R·秦
H·詹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Jindered Biosciences Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jindered Biosciences Co ltd filed Critical Jindered Biosciences Co ltd
Publication of CN115666644A publication Critical patent/CN115666644A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180036332.3A 2020-04-22 2021-04-22 长效兽用抗il31抗体 Pending CN115666644A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063014033P 2020-04-22 2020-04-22
US63/014,033 2020-04-22
US202063014549P 2020-04-23 2020-04-23
US63/014,549 2020-04-23
PCT/US2021/028548 WO2021216810A1 (en) 2020-04-22 2021-04-22 Long-acting anti-il31 antibodies for veterinary use

Publications (1)

Publication Number Publication Date
CN115666644A true CN115666644A (zh) 2023-01-31

Family

ID=78269992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036332.3A Pending CN115666644A (zh) 2020-04-22 2021-04-22 长效兽用抗il31抗体

Country Status (10)

Country Link
US (1) US20230312702A1 (https=)
EP (1) EP4138914A4 (https=)
JP (1) JP2023524643A (https=)
KR (1) KR20230005875A (https=)
CN (1) CN115666644A (https=)
AU (1) AU2021258198A1 (https=)
BR (1) BR112022021216A2 (https=)
CA (1) CA3173864A1 (https=)
MX (1) MX2022013147A (https=)
WO (1) WO2021216810A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
BR112020002871A2 (pt) 2017-08-15 2020-07-28 Kindred Biosciences, Inc. variantes fc de igg para uso veterinário
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
EP4642795A2 (en) * 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
GB202405576D0 (en) * 2024-04-19 2024-06-05 272Bio Ltd VHH antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
CN110114369A (zh) * 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
CN113194984A (zh) * 2018-10-18 2021-07-30 金德雷德生物科学股份有限公司 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体
US11542333B2 (en) * 2019-01-03 2023-01-03 Invetx, Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
US20220169740A1 (en) * 2019-03-20 2022-06-02 Kindred Biosciences, Inc. NGF Antagonists for Medical Use
AU2021238320A1 (en) * 2020-03-18 2022-09-22 Elanco Us Inc. Anti-IL4 receptor antibodies for veterinary use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110114369A (zh) * 2016-10-17 2019-08-09 威隆股份公司 修饰的抗体恒定区
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体
WO2019035010A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110769851A (zh) * 2017-02-24 2020-02-07 金德雷德生物科学股份有限公司 兽用抗il31抗体
CN110769851B (zh) * 2017-02-24 2023-12-08 金德雷德生物科学股份有限公司 兽用抗il31抗体

Also Published As

Publication number Publication date
WO2021216810A1 (en) 2021-10-28
EP4138914A4 (en) 2024-05-22
JP2023524643A (ja) 2023-06-13
BR112022021216A2 (pt) 2022-12-06
AU2021258198A1 (en) 2022-11-17
CA3173864A1 (en) 2021-10-28
MX2022013147A (es) 2023-02-09
US20230312702A1 (en) 2023-10-05
EP4138914A1 (en) 2023-03-01
KR20230005875A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
JP7716441B2 (ja) 獣医用抗ｉｌ－３１抗体
CN115666644A (zh) 长效兽用抗il31抗体
US20240067738A1 (en) Anti-il4 receptor antibodies for veterinary use
US12583917B2 (en) IL17A antibodies and antagonists for veterinary use
WO2018156367A1 (en) Anti-il31 antibodies for veterinary use
HK40088130A (zh) 长效兽用抗il31抗体
EA051090B1 (ru) Анти-il31 антитела длительного действия для применения в ветеринарии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088130

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231205

Address after: Indiana, USA

Applicant after: ELI LILLY AND CO.

Address before: California, USA

Applicant before: Jindered Biosciences Co.,Ltd.